Dayvigo (Lemborexant) Cost in California 2026: Prices, Insurance, and Savings

Lemborexant, sold under the brand name Dayvigo, is a dual orexin receptor antagonist (DORA) taken by mouth to treat insomnia in adults. The FDA approved it in December 2019, and it comes in 5 mg and 10 mg tablets designed for bedtime dosing. Lemborexant is classified as a Schedule IV controlled substance, and currently no FDA-approved generic version exists. In California, patients can access lemborexant through branded Dayvigo, their insurance formulary, manufacturer assistance programs, or compounded versions from state-licensed pharmacies.

What this page can say with confidence: Dayvigo requires a prescription, is regulated as a Schedule IV controlled substance, and is listed on California Medi-Cal's formulary subject to prior authorization. What it cannot responsibly state: a single fixed cash price or manufacturer list price, because those figures change frequently, differ by pharmacy and by insurance plan, and were not reliably sourced in the material available for this draft. Readers who need an exact number for a specific pharmacy or plan should verify it directly rather than relying on any dollar figure printed here or elsewhere.

Why there is no single "Dayvigo price" to quote

Manufacturer list prices (wholesale acquisition cost) and the price an individual patient actually pays are different numbers, and both change over time. List price is set by Eisai and is not something this page can verify against a dated, citable source. Cash-pay price at a given California pharmacy depends on that pharmacy's contracts with wholesalers and pharmacy benefit managers, which is why the same 30-tablet supply can price differently at two pharmacies a few miles apart, and why prices quoted in an article can be stale within months.

If you need a current number, the reliable approach is to call two or three California pharmacies directly (a large chain, an independent pharmacy, and a mail-order pharmacy tied to your insurer if you have one) and compare, or use a real-time pharmacy price comparison tool. Treat any specific dollar figure you read online, including on manufacturer or advocacy sites, as a starting point to verify rather than a guarantee.

The FDA-approved prescribing information for Dayvigo confirms the approved dose strengths (5 mg and 10 mg) and that both are taken once nightly, generally within 7 minutes of going to bed; per-tablet pricing is typically similar between the two strengths at a given pharmacy, but that is a pharmacy-billing pattern, not a regulatory fact.

Does California Medi-Cal cover Dayvigo?

Medi-Cal, California's Medicaid program, includes Dayvigo on its formulary but generally requires prior authorization (PA) before it will pay for the drug. In practice this means a prescriber submits documentation, typically including an insomnia diagnosis and evidence that lower-cost or first-line options were tried or are not appropriate, before the plan approves coverage.

Exact PA turnaround times, appeal procedures, and specific approval criteria are set and updated by the California Department of Health Care Services (DHCS) and can change. This draft does not have a verified, dated source for specific processing-time windows, so readers should confirm current PA requirements and timelines directly with DHCS or their Medi-Cal managed care plan rather than relying on a fixed number.

Clinical guidelines from sleep medicine organizations generally position behavioral treatment, particularly cognitive behavioral therapy for insomnia (CBT-I), as a first-line approach, with medication considered as an adjunct or subsequent step for many patients. A documented CBT-I trial, or a documented contraindication to it, in the medical record is a reasonable thing to discuss with a prescriber if a PA request is anticipated, though this is general practice guidance rather than a guarantee of approval.

How manufacturer savings cards typically work

Eisai has offered manufacturer copay support for commercially insured patients filling Dayvigo prescriptions in the past. The general mechanics of these programs are consistent across most brand-name drug savings cards: they apply as a secondary payer after commercial insurance processes the claim, they are not available to patients on government insurance (Medi-Cal, Medicare, Tricare), and they usually carry an annual dollar cap after which standard copay resumes.

This draft cannot confirm the specific current terms, dollar caps, or eligibility rules for any Dayvigo savings program as of 2026, since those change and were not independently verified for this rewrite. Patients should check Eisai's official patient support materials or ask their pharmacist directly whether a current card exists and what its terms are before assuming a specific benefit amount.

Insurance coverage and formulary tier in California

Most large commercial insurers operating in California maintain formularies that include brand-name insomnia medications like Dayvigo, typically at a preferred-brand or non-preferred-brand tier rather than the lowest generic tier, since there is no generic lemborexant. Exact tier placement and the resulting copay differ by insurer, by employer group, and by plan year, and can also differ between regions of the same insurer (for example, Kaiser Permanente's Northern and Southern California service areas may make independent formulary decisions). None of this can be stated as a fixed number for "California" as a whole.

Medicare Part D enrollees in California also see plan-specific coverage rules and tiering for Dayvigo. Under the Inflation Reduction Act's Medicare Part D redesign, out-of-pocket drug spending for Part D enrollees is capped annually; readers should confirm the current cap amount for the relevant plan year directly with CMS rather than relying on a number that may be out of date by the time this is read.

Is compounded lemborexant legal in California?

Licensed 503A compounding pharmacies in California may compound lemborexant for an individual patient under a valid prescription, consistent with federal compounding law (Section 503A of the Federal Food, Drug, and Cosmetic Act) and California Board of Pharmacy regulations, as generally described in federal compounding guidance.

There is an important limit: a compounding pharmacy generally should not simply reproduce a commercially available drug in the same strength and dosage form unless the prescriber documents a specific clinical reason the FDA-approved product will not work for that patient, such as an inactive-ingredient intolerance. Compounded preparations are not FDA-approved products; they do not go through the same premarket review, and quality can vary between compounding facilities. Anyone considering a compounded version should confirm the pharmacy's current California license through the Board of Pharmacy's license lookup and discuss the rationale with their prescriber, rather than choosing compounding purely on price.

Can you get Dayvigo prescribed by telehealth in California?

California law permits licensed prescribers to evaluate patients by synchronous telehealth and, if clinically appropriate, prescribe medications including Dayvigo. Because lemborexant is a Schedule IV controlled substance, the prescriber must hold valid DEA registration and comply with federal rules governing telehealth prescribing of controlled substances (the Ryan Haight Act framework and related DEA telemedicine flexibilities). These federal controlled-substance telehealth rules have been the subject of periodic extensions and rule changes at the federal level; readers should confirm the current rule status for 2026, since this is a date-sensitive regulatory area rather than a settled fact.

What the clinical evidence actually supports

Lemborexant's approval rested on randomized, placebo-controlled trials in adults with insomnia disorder, generally referred to as the SUNRISE program, which evaluated both objective sleep measures (polysomnography) and patient-reported sleep outcomes over periods up to twelve months. Reported trial findings describe improvements in measures such as time to fall asleep and time spent awake after sleep onset compared with placebo, with somnolence and headache among the more commonly reported side effects. This draft is not carrying forward specific effect-size numbers (for example, minutes of improvement or percentage rates of side effects) from the source material, because the specific citation identifiers attached to those numbers could not be verified against the primary literature for this rewrite; a clinician or editor with direct database access should confirm exact figures before they are republished.

The FDA label carries a warning about next-day impairment, including reduced alertness and potential effects on driving, and advises against activities requiring full alertness until a patient knows how the drug affects them. That warning is a Boxed or highlighted label statement and is the most authoritative source on this point; see the FDA label.

Broader comparisons between orexin receptor antagonists and older insomnia medications (such as benzodiazepine receptor agonists) have been described in the sleep medicine literature as generally favorable on dependence and rebound-insomnia grounds for the newer drug class, but this is an area of ongoing comparative research rather than a single settled finding, and specific study citations should be verified before being used to support individual treatment decisions.

Evidence boundary: what is established, plausible, and unverified

Established: Dayvigo (lemborexant) is FDA-approved for insomnia in adults at 5 mg and 10 mg doses, is Schedule IV, carries an FDA warning about next-day impairment, has no FDA-approved generic as of this writing, and is listed on California Medi-Cal's formulary with a prior authorization requirement.

Plausible but not verified in this draft: specific current cash prices, specific manufacturer savings card terms and caps, specific Medi-Cal PA turnaround times, and specific insurance copay tiers and dollar ranges. These are the kind of facts that are true on a given day at a given pharmacy or plan, but change often enough that a static article cannot responsibly assert them as fixed.

Not established here: any comparison of exact trial effect sizes between lemborexant and other insomnia drugs, and any specific savings-card dollar cap, without a verified current source.

Verification checklist: stable facts vs. date-sensitive facts

Use this before acting on any cost or coverage claim about Dayvigo in California, including claims made elsewhere on this page.

Stable facts (federal regulatory and clinical, unlikely to change month to month):

• Lemborexant is FDA-approved for adult insomnia at 5 mg and 10 mg doses. Verify against the current FDA label.
• Lemborexant is a federal Schedule IV controlled substance.
• No FDA-approved generic lemborexant existed as of this draft's last review date; confirm current status via the FDA Orange Book search before assuming this is still true.
• CBT-I is generally recommended as a first-line insomnia treatment in sleep medicine guidelines, with medication as an adjunct for many patients.

Date-sensitive facts (must be re-verified at the time you act, ideally the same week):

• Cash price at any specific California pharmacy.
• Manufacturer list price (WAC).
• Whether an Eisai or other manufacturer savings card is currently active, and its dollar cap and eligibility rules.
• Medi-Cal's specific prior authorization criteria and turnaround time.
• Your specific commercial or Medicare Part D plan's formulary tier and copay for Dayvigo this plan year.
• Current federal DEA telemedicine rules for prescribing Schedule IV controlled substances without an in-person visit.
• Whether a specific compounding pharmacy holds an active California Board of Pharmacy license.

How to verify quickly:

• Call the pharmacy directly and ask for the current cash price and whether a manufacturer coupon is accepted.
• Ask your insurer's member services line for the current formulary tier and copay, not just what a search tool shows.
• Check the DHCS Medi-Cal provider resources or ask the prescribing clinic's billing staff for the current PA requirements.
• Look up the compounding pharmacy's license status on the California Board of Pharmacy's public license search before filling a compounded prescription.

Frequently asked questions